Taking Cancer On: Recent Episodes
Boehringer Ingelheim
In an effort to simplify the science behind our ambition to ‘drug the undruggable’, this podcast draws back the curtain on cancer research and takes a look at its complex inner workings. Hosted by Sebastian Hermelin (co-founder of the War On Cancer app), each episode welcomes a new expert guest who takes the listener through one of the many stages of cancer research and drug development; from early discovery efforts, through to clinical trials and drug approval.
Expert Guests: Jose Barrueco, M.D. Ph.D. and Petra Blum, M.D. Ph.D., both leading Global Clinical Development teams in Oncology at Boehringer Ingelheim.
In this episode, Jose and Petra discuss cancer immunology and explain what it takes to develop cancer immunotherapies. How can the immune system be used to treat cancer? What is Boehringer Ingelheim contributing to this field? What is the future of cancer immunotherapy? Listen to this episode to find out more!
In this episode, we hear from Dr Scott DeWire, Head of US Business Development at Boehringer Ingelheim (BI) and Dr Andrew Fadden, Head of Corporate Development at Enara Bio about the power of research partnerships in progressing cancer innovation and drug development. Their discussion proves that embracing collaboration is essential in delivering ground-breaking treatments to patients, faster. What do pharmaceutical partnerships entail? What can we gain from collaborating with partners? Do we share the same goals? Listen to this episode to find out more!
In episode 2, our host Sebastian discusses all things clinical with those who have deep insights from personal experience: Ivy Elkins, co-founder of EGFR-Resisters, lung cancer survivor and patient advocate, as well as Dr Victoria Zazulina, Corporate Vice President and Global Head of Oncology Medicine at Boehringer Ingelheim. Do physicians and patients see things in the same light? Listen-in!
In our first episode of the series, Sebastian Hermelin speaks to Dr. Darryl McConnell, Research Site Head at Boehringer Ingelheim Vienna, about targeting ‘undruggable’ cancers and how his team are working tirelessly to find solutions to one of the most challenging areas of cancer research.